Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.

Hamasaki M, Hashizume Y, Yamada Y, Katayama T, Hohjoh H, Fusaki N, Nakashima Y, Furuya H, Haga N, Takami Y, Era T.

Stem Cells. 2012 Nov;30(11):2437-49. doi: 10.1002/stem.1221.

2.

ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.

van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P.

J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.

3.

A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.

Fukuda T, Kanomata K, Nojima J, Kokabu S, Akita M, Ikebuchi K, Jimi E, Komori T, Maruki Y, Matsuoka M, Miyazono K, Nakayama K, Nanba A, Tomoda H, Okazaki Y, Ohtake A, Oda H, Owan I, Yoda T, Haga N, Furuya H, Katagiri T.

Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9. doi: 10.1016/j.bbrc.2008.10.093. Epub 2008 Oct 24.

PMID:
18952055
4.

Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.

Cai J, Orlova VV, Cai X, Eekhoff EM, Zhang K, Pei D, Pan G, Mummery CL, Ten Dijke P.

Stem Cell Reports. 2015 Dec 8;5(6):963-70. doi: 10.1016/j.stemcr.2015.10.020. Epub 2015 Nov 26.

5.

A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.

Ohte S, Shin M, Sasanuma H, Yoneyama K, Akita M, Ikebuchi K, Jimi E, Maruki Y, Matsuoka M, Namba A, Tomoda H, Okazaki Y, Ohtake A, Oda H, Owan I, Yoda T, Furuya H, Kamizono J, Kitoh H, Nakashima Y, Susami T, Haga N, Komori T, Katagiri T.

Biochem Biophys Res Commun. 2011 Apr 1;407(1):213-8. doi: 10.1016/j.bbrc.2011.03.001. Epub 2011 Mar 4.

PMID:
21377447
6.

Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.

Shi S, Cai J, de Gorter DJ, Sanchez-Duffhues G, Kemaladewi DU, Hoogaars WM, Aartsma-Rus A, 't Hoen PA, ten Dijke P.

PLoS One. 2013 Jul 4;8(7):e69096. doi: 10.1371/journal.pone.0069096. Print 2013.

7.

Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Culbert AL, Chakkalakal SA, Theosmy EG, Brennan TA, Kaplan FS, Shore EM.

Stem Cells. 2014 May;32(5):1289-300. doi: 10.1002/stem.1633.

8.

Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.

Fujimoto M, Ohte S, Shin M, Yoneyama K, Osawa K, Miyamoto A, Tsukamoto S, Mizuta T, Kokabu S, Machiya A, Okuda A, Suda N, Katagiri T.

Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):347-52. doi: 10.1016/j.bbrc.2014.11.012. Epub 2014 Nov 15.

PMID:
25446088
9.

Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, Endo K, Awakura T, Fukushi J, Nakashima Y, Chiyonobu T, Kawara A, Nishida Y, Wada I, Akita M, Komori T, Nakayama K, Nanba A, Maruki Y, Yoda T, Tomoda H, Yu PB, Shore EM, Kaplan FS, Miyazono K, Matsuoka M, Ikebuchi K, Ohtake A, Oda H, Jimi E, Owan I, Okazaki Y, Katagiri T.

J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.

10.

[Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].

Katagiri T.

Clin Calcium. 2010 Aug;20(8):1204-11. doi: CliCa100812041211. Review. Japanese.

PMID:
20675931
11.

Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.

Takahashi M, Katagiri T, Furuya H, Hohjoh H.

Gene Ther. 2012 Jul;19(7):781-5. doi: 10.1038/gt.2011.193. Epub 2011 Dec 1.

PMID:
22130450
12.

Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.

Fujimoto M, Ohte S, Osawa K, Miyamoto A, Tsukamoto S, Mizuta T, Kokabu S, Suda N, Katagiri T.

Mol Endocrinol. 2015 Jan;29(1):140-52. doi: 10.1210/me.2014-1301.

13.

Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, Toguchida J.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15438-43. doi: 10.1073/pnas.1510540112. Epub 2015 Nov 30.

14.

[Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].

Katagiri T, Kamizono J, Nakashima Y, Kitoh H, Susami T, Haga N.

Clin Calcium. 2010 Oct;20(10):1510-7. doi: CliCa101015101517. Review. Japanese.

PMID:
20890033
15.

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN.

J Biol Chem. 2012 Oct 26;287(44):36990-8. doi: 10.1074/jbc.M112.365932. Epub 2012 Sep 12.

16.

Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.

de Gorter DJ, Jankipersadsing V, Ten Dijke P.

Curr Pharm Des. 2012;18(27):4087-92.

PMID:
22630080
17.

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Kaplan FS, Glaser DL, Pignolo RJ, Shore EM.

Expert Opin Biol Ther. 2007 May;7(5):705-12. Review.

PMID:
17477807
18.

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB.

J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4.

19.

Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.

Yano M, Kawao N, Okumoto K, Tamura Y, Okada K, Kaji H.

J Biol Chem. 2014 Jun 13;289(24):16966-77. doi: 10.1074/jbc.M113.526038. Epub 2014 May 5.

20.

Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.

Yamamoto R, Matsushita M, Kitoh H, Masuda A, Ito M, Katagiri T, Kawai T, Ishiguro N, Ohno K.

J Bone Miner Metab. 2013 Jan;31(1):26-33. doi: 10.1007/s00774-012-0380-2. Epub 2012 Aug 24.

PMID:
23011467

Supplemental Content

Support Center